PROC (procapsgroup.com) Bozor qiymatining balans qiymatiga nisbati

Procaps Group (PROC) kompaniyasining rasmiy ramzlari

Procaps Group S.A. daromadlarining bashorat qilinuvchanligi sanoat yetakchilari bilan tuzilgan ko'p yillik shartnomalarga asoslangan. Bozor kapitalizatsiyasi va balans qiymati o'rtasidagi tarixiy bog'liqlik likvidlikning aktivlar baholashiga ta'sirini ko'rsatadi, bunda ko'rsatkich 6.60 darajasida mustahkamlandi. CDMO B2B modeli yuqori marja va FCF oqimlarini kafolatlaydi, garchi quvvatlarni kengaytirish davrida muvofiqlik xarajatlari sof foyda o'sishini cheklasa-da.

PROC Procaps Group Corp: Balans qiymatiga nisbatan bozor qiymati 04.07.2022 - 31.12.2024 oraligʻida

Procaps Group (PROC) moliyaviy va bozor koʻrsatkichlari kesimi

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya narxi Procaps Group S.A.|PROC - Konsensus maqsadli narx
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor qiymati Procaps Group SA|PROC - Biznesning to‘liq qiymati
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya hisobiga balans qiymati Procaps|PROC - Kompaniyaning buxgalteriya qiymati|Bozor kapitallashuvining balans qiymatiga nisbati procapsgroup.com|PROC - Kompaniyaning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Qarzning xususiy kapitalga nisbati Procaps Group S.A.|PROC - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Qisqa muddatli qarzning o'z kapitaliga nisbati Procaps Group SA|PROC - Kompaniyaning umumiy qarzi|Balans kapitallashuviga qarzlar Procaps Group SA
Kompaniyaning dastlabki tahlili:Procaps Group S.A. - PROC
Procaps Group SA original mahsuloti

Procaps Group S.A. (PROC) aktivlarining sifatini baholashda, bozor kutuvlarini biznesning haqiqiy qiymati bilan muvofiqlashtirish muhimdir. Ushbu narxning buki ko'rsatkichi joriy bozor kapitalizatsiyasi va emitentning sof aktivlari o'rtasidagi bog'liqlikni aks ettiradi. Mazkur metrika aksiyalar balans hisoboti bazasiga nisbatan haddan tashqari qimmat yoki arzon baholanganligini ochib beradi. Dori vositalarini yetkazib berish sohasidagi innovator uchun yuqori premium R&D va avtomatlashtirishga kiritilgan investitsiyalar bilan asoslanadi, bu esa kompaniyaning intellektual kapitalining bozor qiymatini tasdiqlaydi.

Asosiy raqobatchilar

HLN (Haleon plc) - Bozor kapitallashuvining balans qiymatiga nisbati|KVUE (kenvue.com) - Kapitallashuvning sof aktivlarga nisbati|Bozor qiymatining balans qiymatiga nisbati Verona Pharma VRNA|Sof aktivlarga nisbatan bozor kapitallashuvi Jyong Biotech Limited|Ligand Pharma (LGND) - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati Amneal Corp (AMRX)|Bozor kapitallashuvining balans qiymatiga nisbati PRGO (Perrigo Company plc)|alvotech.com - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati Liquidia (LQDA)|GLPG: Balans qiymatiga nisbatan bozor qiymati|ANIP (ANI Pharma) - Bozor qiymatining balans qiymatiga nisbati|Afrezza (MNKD) - Kapitallashuvning sof aktivlarga nisbati|AMPH (Amphastar Pharmaceuticals) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati pacira.com (PCRX)|ARS Pharmaceuticals, Inc. (SPRY) - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati TBPH (Theravance Biopharma Inc)|AQST: Bozor qiymatining balans qiymatiga nisbati|SCPH - Bozor qiymatining balans qiymatiga koeffitsiyenti|Kapitallashuvning sof aktivlarga nisbati Tectonic TECX|TNXP - Bozor kapitallashuvining balans qiymatiga multiplikatori|Bozor kapitallashuvining balans qiymatiga nisbati sxtchina.com SXTC|Eupraxia Pharmaceuticals Inc. (EPRX) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati BHST (BioHarvest)|Bozor qiymatining balans qiymatiga koeffitsiyenti EXOZ|Oramed Pharmaceuticals (ORMP) - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati ENTX (enterabio.com)|MindWalk Holdings Inc. (HYFT) - Bozor qiymatining balans qiymatiga nisbati|ABVC BioPharma Inc. - Sof aktivlarga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati Cumberland Pharma (CPIX)|QNTM: Balans qiymatiga nisbatan bozor qiymati|Bozor qiymatining balans qiymatiga nisbati FGEN|telomirpharma.com (TELO) - Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor kapitallashuvining balans qiymatiga nisbati RANI|Kapitallashuvning sof aktivlarga nisbati Synergy CHC Corporation|Bozor kapitallashuvining balans qiymatiga nisbati RLYB|Bozor kapitallashuvining balans qiymatiga nisbati LEXX (lexariabioscience.com)|Pulmatrix, Inc. (PULM) - Bozor qiymatining balans qiymatiga nisbati|Pheton Holdings Limited - Sof aktivlarga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati APM (Aptorum)|Lyra Therapeutics Inc. (LYRA) - Balans qiymatiga nisbatan bozor kapitallashuvi|Kapitallashuvning sof aktivlarga nisbati Impact BioMedical IBO|TNF Pharmaceuticals, Inc. (TNFA) - Balans qiymatiga nisbatan bozor qiymati|cbdMD Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining xususiy kapitalga nisbati PRFX|Altamira Therapeutics (CYTO) - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati LIPO (Lipella Pharmaceuticals Inc)|OPTN: Bozor qiymatining balans qiymatiga nisbati|PIRS - Bozor qiymatining balans qiymatiga koeffitsiyenti|Petros Pharmaceuticals - Kapitallashuvning sof aktivlarga nisbati|QLI: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati ACELYRIN (SLRN)|Sof aktivlarga nisbatan bozor kapitallashuvi TFF Pharmaceuticals Inc.